Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACA Syrup Phase II trial in young children with sickle cell anemia
PACTR202603500795589Phase 2Not yet recruiting
- Sponsor
- Institut de Recherche en Sciences de la Santé
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hydroxyurea in sickle cell disease (SCD) and sickle cell anemia (SCA) (2 arms), sponsored by Institut de Recherche en Sciences de la Santé. Primary endpoint: Reduction in seizure frequency. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)
Beyond the preview
Go deeper on PACTR202603500795589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202603500795589.